WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today’s webcast and conference call.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “I’m pleased to report strong third quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and equipment sales in the quarter, with each delivering year-over-year and sequential growth. In new modalities, we achieved record sales in the quarter and our differentiated technology continues to serve us well. We are further encouraged by continued strength in Filtration, consumables, and Pharma, as well as order recovery in Chromatography. With clear line of sight, we are narrowing the 2024 revenue guidance shared in our September update, maintaining the midpoint, and we are optimistic about our opportunity funnel as we move into 2025.”
Q3 2024 BUSINESS HIGHLIGHTS
FINANCIAL PERFORMANCE
Q3 2024 FINANCIAL PERFORMANCE (compared to prior year, Q3 2023, except as noted)
All adjusted figures are non-GAAP and, except for earnings per share, are rounded to the nearest million.
MARGIN SUMMARY
| GAAP Margins | Q3 2024 | Q3 2023 | Q3-YTD 2024 | Q3-YTD 2023 | ||||
| Gross Margin | 50.0% | 25.9% | 50.5% | 42.9% | ||||
| Operating (EBIT) Margin | (5.1)% | 3.3% | 0.3% | 8.1% | ||||
| Adjusted (non-GAAP) Margins | Q3 2024 | Q3 2023 | Q3-YTD 2024 | Q3-YTD 2023 | ||||
| Gross Margin | 50.7% | 42.0% | 50.3% | 47.8% | ||||
| Operating (EBIT) Margin | 14.9% | 3.7% | 12.2% | 12.5% | ||||
| EBITDA Margin | 20.7% | 10.2% | 17.6% | 18.1% | ||||
Cash, cash equivalents and short-term investments at September 30, 2024, were $784 million, compared to $751 million at December 31, 2023.
FINANCIAL GUIDANCE FOR FULL YEAR 2024
All Adjusted figures are non-GAAP
Our financial guidance for the full year 2024 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance includes the expected impact of businesses acquired in 2023 (FlexBiosys and Metenova) and excludes the impact of any potential or pending business acquisitions in 2024, and future fluctuations in foreign currency exchange rates.
| CURRENT GUIDANCE (at November 12, 2024) | ||||
| FY 2024 | GAAP | Adjusted (non-GAAP) | ||
| Total Reported Revenue | $630M - $639M | $630M - $639M | ||
| Year-over-Year Change | 0% - 1% | 0% - 1% | ||
| Base Revenue Growth | - | (1%) - 0% | ||
| Gross Margin | 49.5% - 50.5% | 49.5% - 50.5% | ||
| Income from Operations | $12M - $17M | $80M - $85M | ||
| Operating Margin | 2% - 3% | 12.5% - 13.5% | ||
| Other Income (Expense) | $10M | $27M | ||
| Adjusted EBITDA Margin | - | 17.5% - 18.5% | ||
| Tax Rate on Pre-Tax Income | 33% | 20% | ||
| Net Income | $14M - $18M | $85M - $89M | ||
| Earnings Per Share - Diluted | $0.25 - $0.32 | $1.50 - $1.58 | ||
Conference Call and Webcast Access
Repligen will host a conference call and webcast today, November 12, 2024, at 8:30 a.m. ET, to discuss third quarter 2024 financial results, corporate developments and financial guidance for 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 3384562.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following Adjusted (non-GAAP) measures of financial performance are included in this release: organic revenue growth, base revenue growth; adjusted cost of goods sold, adjusted gross profit and adjusted gross margin; adjusted R&D expense and adjusted SG&A expense; adjusted income from operations and adjusted operating margin; adjusted pre-tax income; adjusted net income; adjusted earnings per share (diluted); adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides base revenue and base revenue growth rates, which exclude COVID-related revenue, and the impact of acquisition revenue for current year periods that have no prior year comparables, to facilitate a comparison of its current revenue performance to its past performance. The Company provides the impact of foreign currency translation, to enable determination of revenue growth rates at constant currency. To calculate the impact of foreign currency translation, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior year periods.
The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs; restructuring charges including the costs of severance and accelerated depreciation among other charges; incremental costs attributed to CEO transition; contingent consideration related to the Company’s acquisitions; intangible amortization costs; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.
NOTE:
All reconciliations of above GAAP figures (reported or guidance) to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. When analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.
Forward-Looking Statements
This release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in the release do not constitute guarantees of future performance. Investors are cautioned that statements in this release which are not strictly historical statements, including, among others; statements regarding the expected impact of the Restatement (as defined in the Current Report on Form 8-K filed on September 18, 2024) and change in accounting treatment, including on the Company’s overall business operations, previously reported cash and cash equivalent balances, and strategic outlook; statements regarding the Company’s internal controls over financial reporting and ongoing internal reviews and assessments; any express or implied statements or guidance regarding current or future financial performance and position, including our updated 2024 financial guidance and related assumptions; expected demand in the markets in which we operate (including the belief that such markets will improve and the impact of such improvement on our business); the expected performance of our business; the expected performance and success of our strategic partnerships and integration of our acquired businesses, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” “projected,” “estimated” or “could” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including: that the Company has underestimated the scope and impact of the Restatement, risks and uncertainties around the effectiveness of the Company’s disclosure controls and procedures and the effectiveness of the Company’s internal control over financial reporting, the risk that the Company’s restated financial statements may take longer to complete than expected; our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds, including to achieve our updated 2024 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate any acquired businesses (including Metenova and FlexBiosys) into our business, or to close potential or pending acquisitions (including Tantti) in a timely manner or at all, and achieve the expected benefits of such acquisitions; that demand for our products could continue to decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; and other risks detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including Annual Report on Form 10-K for the year ended December 31, 2023 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q (including for the quarters ended March 31, 2024 and June 30, 2024), current reports on Form 8-K, and any subsequent filings with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements; therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law. Further, investors are cautioned that the Prior Period Financial Statements (as defined in the Current Report on Form 8-K filed on September 18, 2024), and related investor communications, should no longer be relied upon; such communications include earnings releases, press releases, shareholder communications, investor presentations and other communications describing relevant portions of the Prior Period Financial Statements.
Repligen Contact:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
This email address is being protected from spambots. You need JavaScript enabled to view it.
| REPLIGEN CORPORATION | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (Unaudited, amounts in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 154,834 | $ | 141,156 | $ | 466,784 | $ | 465,630 | |||||||
| Royalty and other revenue | 37 | 36 | 108 | 111 | |||||||||||
| Total revenue | 154,871 | 141,192 | 466,892 | 465,741 | |||||||||||
| Costs and expenses: | |||||||||||||||
| Cost of goods sold | 77,383 | 104,634 | 231,088 | 265,786 | |||||||||||
| Research and development | 9,710 | 10,577 | 31,523 | 32,437 | |||||||||||
| Selling, general and administrative | 75,610 | 55,583 | 202,894 | 160,954 | |||||||||||
| Contingent consideration | - | (34,292 | ) | - | (31,266 | ) | |||||||||
| 162,703 | 136,502 | 465,505 | 427,911 | ||||||||||||
| (Loss) income from operations | (7,832 | ) | 4,690 | 1,387 | 37,830 | ||||||||||
| Investment income | 9,130 | 6,662 | 27,534 | 18,112 | |||||||||||
| Interest expense | (5,121 | ) | (407 | ) | (15,269 | ) | (1,227 | ) | |||||||
| Amortization of debt issuance costs | (429 | ) | (459 | ) | (1,432 | ) | (1,373 | ) | |||||||
| Other income (expenses), net | 3,104 | 895 | (647 | ) | 1,500 | ||||||||||
| (Loss) income before income taxes | (1,148 | ) | 11,381 | 11,573 | 54,842 | ||||||||||
| Income tax (benefit) provision | (495 | ) | (5,542 | ) | 3,218 | 2,796 | |||||||||
| Net (loss) income | $ | (653 | ) | $ | 16,923 | $ | 8,355 | $ | 52,046 | ||||||
| (Loss) earnings per share: | |||||||||||||||
| Basic | $ | (0.01 | ) | $ | 0.30 | $ | 0.15 | $ | 0.93 | ||||||
| Diluted | $ | (0.01 | ) | $ | 0.30 | $ | 0.15 | $ | 0.91 | ||||||
| Weighted average shares outstanding: | |||||||||||||||
| Basic | 56,012,322 | 55,765,639 | 55,896,378 | 55,687,574 | |||||||||||
| Diluted | 56,012,322 | 56,939,684 | 56,315,276 | 56,933,467 | |||||||||||
| Balance Sheet Data: | September 30, 2024 | December 31, 2023 (Restated) | |||||
| Cash, cash equivalents and marketable securities | $ | 783,964 | $ | 751,323 | |||
| Working capital | 1,023,204 | 946,404 | |||||
| Total assets | 2,830,644 | 2,831,185 | |||||
| Long-term obligations | 705,592 | 701,398 | |||||
| Accumulated earnings | 441,223 | 432,868 | |||||
| Stockholders' equity | 2,016,686 | 1,964,845 | |||||
| REPLIGEN CORPORATION | |||||||
| RECONCILIATIONS OF GAAP to NON-GAAP FINANCIAL MEASURES | |||||||
| (Unaudited, amounts in thousands, except percentage and earnings per share data) | |||||||
| In all tables below, totals may not add due to rounding | |||||||
| Reconciliation of Reported Revenue (GAAP) Growth to Organic Revenue Growth (Non-GAAP) | |||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||
| TOTAL REPORTED REVENUE (GAAP) GROWTH | 10% | (30%) | 0% | (24%) | |||
| Acquisition revenue | (3%) | 0% | (3%) | 0% | |||
| Currency exchange | 0% | (1%) | 1% | 0% | |||
| ORGANIC REVENUE GROWTH (NON-GAAP) | 7% | (31%) | (2%) | (24%) | |||
| Reconciliation of Total Revenue (GAAP) to Base Revenue (Non-GAAP) | |||||||||||||||||||||
| Three Months Ended September 30, | % Change | Nine Months Ended September 30, | % Change | ||||||||||||||||||
| 2024 | 2023 (2) (Restated) | 2024 vs 2023 | 2024 | 2023 (2) (Restated) | 2024 vs 2023 | ||||||||||||||||
| TOTAL REPORTED REVENUE (GAAP) | $ | 154,871 | $ | 141,192 | 10% | $ | 466,892 | $ | 465,741 | 0% | |||||||||||
| COVID-related revenue | - | - | 0% | (11,462 | ) | (6,929 | ) | 65% | |||||||||||||
| Acquisition revenue | (4,108 | ) | - | n/a | (14,848 | ) | - | n/a | |||||||||||||
| BASE REVENUE (NON-GAAP) (1) | $ | 150,763 | $ | 141,192 | 7% | $ | 440,582 | $ | 458,812 | (4%) | |||||||||||
| Reconciliation of Income from Operations (GAAP) to Adjusted Income from Operations (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| (LOSS) INCOME FROM OPERATIONS (GAAP) | $ | (7,832 | ) | $ | 4,690 | $ | 1,387 | $ | 37,830 | ||||||
| ADJUSTMENTS TO (LOSS) INCOME FROM OPERATIONS (GAAP): | |||||||||||||||
| Acquisition and integration costs | 1,819 | 3,147 | 4,897 | 4,927 | |||||||||||
| Restructuring(3) | 2,579 | 24,012 | 1,939 | 24,012 | |||||||||||
| Incremental costs attributed to CEO transition(4) | 17,379 | - | 22,346 | - | |||||||||||
| Contingent consideration | - | (34,292 | ) | - | (31,266 | ) | |||||||||
| Intangible amortization | 8,570 | 7,610 | 25,926 | 22,683 | |||||||||||
| Other(5) | 586 | - | 586 | - | |||||||||||
| ADJUSTED INCOME FROM OPERATIONS (NON-GAAP) | $ | 23,101 | $ | 5,167 | $ | 57,081 | $ | 58,186 | |||||||
| OPERATING (EBIT) MARGIN | (5.1% | ) | 3.3% | 0.3% | 8.1% | ||||||||||
| ADJUSTED OPERATING (EBIT) MARGIN | 14.9% | 3.7% | 12.2% | 12.5% | |||||||||||
| Reconciliation of Net (Loss) Income (GAAP) to Adjusted Net Income (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| NET (LOSS) INCOME (GAAP) | $ | (653 | ) | $ | 16,923 | $ | 8,355 | $ | 52,046 | ||||||
| ADJUSTMENTS TO NET (LOSS) INCOME (GAAP): | |||||||||||||||
| Acquisition and integration costs | 1,819 | 3,147 | 4,897 | 4,927 | |||||||||||
| Restructuring(3) | 2,345 | 24,012 | 1,705 | 24,012 | |||||||||||
| Incremental costs attributed to CEO transition(4) | 17,379 | - | 22,346 | - | |||||||||||
| Contingent consideration | - | (34,292 | ) | - | (31,266 | ) | |||||||||
| Intangible amortization | 8,570 | 7,610 | 25,926 | 22,683 | |||||||||||
| Non-cash interest expense | 3,610 | 138 | 10,610 | 414 | |||||||||||
| Amortization of debt issuance costs | 429 | 459 | 1,432 | 1,373 | |||||||||||
| Foreign currency impact of certain intercompany loans (6) | (2,819 | ) | - | 626 | - | ||||||||||
| Other(5) | 586 | - | 586 | - | |||||||||||
| Tax effect of non-GAAP charges | (7,223 | ) | (4,825 | ) | (12,809 | ) | (8,162 | ) | |||||||
| ADJUSTED NET INCOME (NON-GAAP) | $ | 24,043 | $ | 13,172 | $ | 63,674 | $ | 66,027 | |||||||
| Reconciliation of (Loss) Earnings Per Share (GAAP) to Adjusted Earnings Per Share (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| (LOSS) EARNINGS PER SHARE (GAAP) - DILUTED | $ | (0.01 | ) | $ | 0.30 | $ | 0.15 | $ | 0.91 | ||||||
| ADJUSTMENTS TO (LOSS) EARNINGS PER SHARE (GAAP) - DILUTED: | |||||||||||||||
| Acquisition and integration costs | 0.03 | 0.06 | 0.09 | 0.09 | |||||||||||
| Restructuring(3) | 0.04 | 0.42 | 0.03 | 0.42 | |||||||||||
| Incremental costs attributed to CEO transition(4) | 0.31 | - | 0.40 | - | |||||||||||
| Contingent consideration | - | (0.60 | ) | - | (0.55 | ) | |||||||||
| Intangible amortization | 0.15 | 0.13 | 0.46 | 0.40 | |||||||||||
| Non-cash interest expense | 0.06 | 0.00 | 0.19 | 0.01 | |||||||||||
| Amortization of debt issuance costs | 0.01 | 0.01 | 0.03 | 0.02 | |||||||||||
| Foreign currency impact of certain intercompany loans (6) | (0.05 | ) | - | 0.01 | - | ||||||||||
| Other(5) | 0.01 | - | 0.01 | - | |||||||||||
| Tax effect of non-GAAP charges | (0.13 | ) | (0.08 | ) | (0.23 | ) | (0.14 | ) | |||||||
| ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED(7) | $ | 0.43 | $ | 0.23 | $ | 1.13 | $ | 1.16 | |||||||
| Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| NET (LOSS) INCOME (GAAP) | $ | (653 | ) | $ | 16,923 | $ | 8,355 | $ | 52,046 | ||||||
| ADJUSTMENTS: | |||||||||||||||
| Investment income | (9,130 | ) | (6,662 | ) | (27,534 | ) | (18,112 | ) | |||||||
| Interest expense | 5,121 | 407 | 15,269 | 1,227 | |||||||||||
| Amortization of debt issuance costs | 429 | 459 | 1,432 | 1,373 | |||||||||||
| Income tax provision | (495 | ) | (5,542 | ) | 3,218 | 2,796 | |||||||||
| Depreciation | 8,825 | 12,186 | 25,297 | 28,530 | |||||||||||
| Intangible amortization(8) | 8,598 | 7,637 | 26,009 | 22,765 | |||||||||||
| EBITDA (NON-GAAP) | 12,695 | 25,408 | 52,046 | 90,625 | |||||||||||
| OTHER ADJUSTMENTS: | |||||||||||||||
| Acquisition and integration costs | 1,819 | 3,147 | 4,897 | 4,927 | |||||||||||
| Restructuring (3)(9) | 2,345 | 20,196 | 1,686 | 20,196 | |||||||||||
| Incremental costs attributed to CEO transition(4) | 17,379 | - | 22,346 | - | |||||||||||
| Contingent consideration | - | (34,292 | ) | - | (31,266 | ) | |||||||||
| Foreign currency impact of certain intercompany loans (6) | (2,819 | ) | - | 626 | - | ||||||||||
| Other(5) | 586 | - | 586 | - | |||||||||||
| ADJUSTED EBITDA (NON-GAAP) | $ | 32,005 | $ | 14,459 | $ | 82,187 | $ | 84,482 | |||||||
| ADJUSTED EBITDA MARGIN (NON-GAAP) | 20.7% | 10.2% | 17.6% | 18.1% | |||||||||||
| Reconciliation of Cost of Goods Sold (GAAP) to Adjusted Cost Goods Sold (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| COST OF GOODS SOLD (GAAP) | $ | 77,383 | $ | 104,634 | $ | 231,088 | $ | 265,786 | |||||||
| ADJUSTMENT TO COST OF GOODS SOLD (GAAP): | |||||||||||||||
| Acquisition and integration costs | (90 | ) | (26 | ) | (289 | ) | (33 | ) | |||||||
| Restructuring(3) | (912 | ) | (22,711 | ) | 1,050 | (22,711 | ) | ||||||||
| ADJUSTED COST OF GOODS SOLD (NON-GAAP) | $ | 76,381 | $ | 81,897 | $ | 231,849 | $ | 243,042 | |||||||
| GROSS MARGIN (GAAP) | 50.0% | 25.9% | 50.5% | 42.9% | |||||||||||
| ADJUSTED GROSS MARGIN (NON-GAAP) | 50.7% | 42.0% | 50.3% | 47.8% | |||||||||||
| Reconciliation of R&D Expense (GAAP) to Adjusted R&D Expense (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| R&D EXPENSE (GAAP) | $ | 9,710 | $ | 10,577 | $ | 31,523 | $ | 32,437 | |||||||
| ADJUSTMENT TO R&D EXPENSE (GAAP): | |||||||||||||||
| Acquisition and integration costs | (84 | ) | - | (200 | ) | 7 | |||||||||
| Restructuring(3) | - | (35 | ) | (449 | ) | (35 | ) | ||||||||
| ADJUSTED R&D EXPENSE (NON-GAAP) | $ | 9,626 | $ | 10,542 | $ | 30,874 | $ | 32,409 | |||||||
| Reconciliation of SG&A Expense (GAAP) to Adjusted SG&A Expense (Non-GAAP) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | ||||||||||||
| SG&A EXPENSE (GAAP) | $ | 75,610 | $ | 55,583 | $ | 202,894 | $ | 160,954 | |||||||
| ADJUSTMENTS TO SG&A EXPENSE (GAAP): | |||||||||||||||
| Acquisition and integration costs | (1,643 | ) | (3,121 | ) | (4,407 | ) | (4,901 | ) | |||||||
| Restructuring(3) | (1,667 | ) | (1,266 | ) | (2,540 | ) | (1,266 | ) | |||||||
| Incremental costs attributed to CEO transition(4) | (17,379 | ) | - | (22,346 | ) | - | |||||||||
| Intangible amortization | (8,570 | ) | (7,610 | ) | (25,926 | ) | (22,683 | ) | |||||||
| Other(5) | (586 | ) | - | (586 | ) | - | |||||||||
| ADJUSTED SG&A EXPENSE (NON-GAAP) | $ | 45,764 | $ | 43,586 | $ | 147,089 | $ | 132,104 | |||||||
| Reconciliation of Net Income (GAAP) Guidance to Adjusted Net Income (Non-GAAP) Guidance | |||||||
| Twelve months ending December 31, 2024 | |||||||
| Low End | High End | ||||||
| GUIDANCE ON NET INCOME (GAAP) | $ | 14,000 | $ | 18,000 | |||
| ADJUSTMENTS TO GUIDANCE ON NET INCOME (GAAP): | |||||||
| Acquisition and integration costs | 7,040 | 7,040 | |||||
| Restructuring | 2,944 | 2,944 | |||||
| Incremental costs attributed to CEO transition | 21,730 | 21,730 | |||||
| Contingent consideration | 1,500 | 1,500 | |||||
| Anticipated pre-tax amortization of acquisition-related intangible assets | 34,543 | 34,543 | |||||
| Non-cash interest expense | 14,245 | 14,245 | |||||
| Amortization of debt issuance costs | 1,843 | 1,843 | |||||
| Foreign currency impact of certain intercompany loans | 626 | 626 | |||||
| Tax effect of non-GAAP charges | (14,124 | ) | (14,124 | ) | |||
| Other | 586 | 586 | |||||
| Guidance rounding adjustment | 67 | 67 | |||||
| GUIDANCE ON ADJUSTED NET INCOME (NON-GAAP) | $ | 85,000 | $ | 89,000 | |||
| Reconciliation of Earnings Per Share (GAAP) Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance | |||||||
| Twelve months ending December 31, 2024 | |||||||
| Low End | High End | ||||||
| GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED | $ | 0.25 | $ | 0.32 | |||
| ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED: | |||||||
| Acquisition and integration costs | 0.12 | 0.12 | |||||
| Restructuring | 0.05 | 0.05 | |||||
| Incremental costs attributed to CEO transition | 0.38 | 0.38 | |||||
| Contingent consideration | 0.03 | 0.03 | |||||
| Anticipated pre-tax amortization of acquisition-related intangible assets | 0.61 | 0.61 | |||||
| Non-cash interest expense | 0.25 | 0.25 | |||||
| Amortization of debt issuance costs | 0.03 | 0.03 | |||||
| Foreign currency impact of certain intercompany loans | 0.01 | 0.01 | |||||
| Tax effect of non-GAAP charges | (0.25 | ) | (0.25 | ) | |||
| Other | 0.01 | 0.01 | |||||
| Guidance rounding adjustment | 0.00 | 0.00 | |||||
| GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED | $ | 1.50 | $ | 1.58 | |||
| FOOTNOTES FOR ALL TABLES ABOVE (amounts in thousands): | |
| (1) | Base revenue (Non-GAAP) excludes COVID-related revenue and excludes acquisition-related revenue contribution in current period for which there was no prior year comparable. |
| (2) | For the three- and nine-month reporting periods ended September 30, 2023, there was $1,048 and $1,763 respectively in acquisition revenue that has been added to Base Revenue (Non-GAAP) for comparative purposes, as this revenue is now appropriately included in our year-over-year Base Revenue growth percentage of 7% and (4%) respectively. At one year post-acquisition, those associated revenues are considered part of ongoing Base business. |
| (3) | In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. The Company continued further restructuring activities during the three months ended September 30, 2024 including severance, employee-related and facility exit costs. Included in cost of goods sold for the three and nine months ended September 30, 2024 is $572 and $3,607 respectively, for benefit received on the sale of inventory that had previously been reserved as part of the Restructuring Plan. |
| (4) | Incremental stock compensation expense recorded during the three and nine months ended September 30, 2024 of $17,379 and $22,346 respectively, attributable to the transition of the Company’s Chief Executive Officer (“CEO”) to Executive Chair of the Board announced by the Company on June 12, 2024. The incremental stock compensation expense was the result of the modification of the unvested equity awards held by the CEO immediately prior to the modification. This resulted in the revalue of his unvested awards and a change in his remaining requisite service period due to his change in duties upon transitioning to Executive Chair of the Board. |
| (5) | Includes a one time event relating to a cybersecurity incident, net of insurance. |
| (6) | During the three and nine months ended September 30, 2024 we recorded foreign currency adjustments on certain intercompany loans of ($2,819) and $626 respectively. The impact was recorded to the Other income (expenses), net line item within the Condensed Consolidated Statements of Operations. |
| (7) | GAAP loss per share - diluted for the three months ended September 30, 2024, was determined excluding the effect of 358,372 shares of dilutive shares as the impact of such shares would have been antidilutive due to the net loss for the period, while the adjusted earnings per share - diluted for the same period was determined based upon diluted shares of 56,370,694 shares. |
| (8) | Includes amortization of milestone payments in accordance with GAAP of $28 for the three months ended September 30, 2024 and 2023 and $83 for the nine months ended September 30, 2024 and 2023. |
| (9) | Excludes $19 of accelerated depreciation related to the restructuring plan for the nine months ended September 30, 2024. This amount is included in the depreciation line item of this table for that period. |
| Last Trade: | US$138.90 |
| Daily Change: | 10.41 8.10 |
| Daily Volume: | 711,222 |
| Market Cap: | US$7.780B |
November 05, 2024 July 30, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
